Vernalis is a UK-based specialty pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.
The individuals who make up the Board and Management team of Vernalis draw on a rich and diverse background of experience from within and outside of the biotech industry.
The Board considers that good corporate governance is an essential element of achieving its overall objectives. Find out more about the Board, as well as the Committees they sit on
To view Vernalis' latest Corporate Profile please follow this link
Product Pipeline
The discovery of novel medicines to treat human disease is the cornerstone of our business. To find out more details of the conditions we are seeking to treat - view our product pipeline.